06/22/2012 334 ORDER: After a bench trial and the Court's review of the parties' post-trial briefing, the Court finds that the Defendants', Mylan Pharmaceuticals Inc., et al. and Sandoz, Inc. et al., abbreviated new drug applications infringe all of the asserted claims of the Plaintiffs' patents and that none of the asserted claims are invalid or unenforceable. The full opinion of the Court's findings of fact and conclusions of law will follow immediately after the parties have had the opportunity to review it in order to request redactions of any proprietary information it may contain. See Dkt. No. 332 in 08-cv-7611.) (Signed by Judge Barbara S. Jones on 6/22/2012) Filed In Associated Cases: 1:08-cv-07611-BSJ -AJP, 1:09-cv-08824-BSJ(laq) (Entered: 06/22/2012)
Market Data 
Markets 
AI
